Lilly buys into one‑time edits
Eli Lilly announced an acquisition of Vere Therapeutics to advance one‑time, in‑vivo gene‑editing cardiovascular treatments, a sign that editing is expanding beyond rare blood disorders. Lilly described VERVE‑102 as a Phase 1b program with FDA fast‑track designation and potential to scale gene editing into broader cardiovascular care. (pharmexec.com)
Gene editing started in medicine with rare diseases because doctors could target a small group of patients with one broken gene. Eli Lilly is now betting the same one-time approach can move into heart disease, a market measured in millions of people instead of thousands. (prnewswire.com) The basic idea is simple: change the DNA instructions inside a liver cell once, and the cell may keep following the new instruction for years. Verve’s lead program, called VERVE-102, is designed to switch off a gene called proprotein convertase subtilisin/kexin type 9, which helps control low-density lipoprotein cholesterol in the blood. (vervetx.com) That gene matters because people already take antibody drugs that block the proprotein convertase subtilisin/kexin type 9 protein after it is made. VERVE-102 goes one step earlier by trying to stop the liver from making as much of that protein in the first place. (vervetx.com) To do that, the treatment carries two pieces into the body: a base editor, which works like a pencil that changes one DNA letter, and a guide ribonucleic acid, which works like a street address that tells the pencil where to go. Verve says both are packaged in a lipid nanoparticle, a tiny fat bubble that delivers them to the liver after an intravenous infusion. (vervetx.com) The patients Lilly is chasing first are not the average person with borderline cholesterol. The Phase 1b Heart-2 study is enrolling adults with heterozygous familial hypercholesterolemia or premature coronary artery disease, which are groups with very high lifetime risk and stubbornly elevated cholesterol. (clinicaltrials.gov) Heterozygous familial hypercholesterolemia affects about 1 in 250 people and pushes low-density lipoprotein cholesterol high from birth. That makes it a useful first test case for a one-time edit, because the disease is driven by lifelong exposure to the same harmful cholesterol burden. (prnewswire.com) The United States Food and Drug Administration gave VERVE-102 Fast Track designation on April 11, 2025. Verve said that status covers patients with hyperlipidemia and high lifetime cardiovascular risk, and it can speed meetings and review as the program advances. (vervetx.com) Lilly agreed on June 17, 2025 to buy Verve for up to $1.3 billion, including $10.50 a share in cash plus a contingent value right worth up to $3.00 a share if a milestone is hit. The deal gave Lilly a clinical-stage gene-editing program in cardiovascular disease instead of another early research partnership. (prnewswire.com) Lilly completed the acquisition on July 28, 2025, and Verve became a wholly owned subsidiary. Lilly said it wanted Verve’s gene-editing platform alongside its existing cardiometabolic business, which already includes large franchises in diabetes and obesity. (vervetx.com) What Lilly is really buying is a chance to turn cholesterol treatment from a lifetime routine into a single procedure. If VERVE-102 proves safe and durable, gene editing would no longer be confined mainly to rare blood disorders and could start competing in one of the biggest chronic disease categories in medicine. (pharmexec.com)
